S100A10 and colorectal carcinoma: In addition, the expression of S100A10 in the nuclei and cytoplasm of rectal cancer after nCRT and liver metastatic foci increased compared with that in rectal cancer without nCRT, indicating that SUMO-modified S100A10 may be a new target for CRC clinical therapy.